Skip to main content
Top
Published in: Annals of General Psychiatry 1/2010

Open Access 01-04-2010 | Meeting abstract

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder

Authors: Julio Zarra, Luisa Schmidt

Published in: Annals of General Psychiatry | Special Issue 1/2010

Login to get access

Excerpt

Galantamine is a reversible, competitive cholinesterasa inhibitor that also allosterically modulates nicotine acetylcholine receptors. Inhibition of acetylcholinesterase, the enzyme responsible for hydrolisis of acetylcholine at the cholinergic cognitive impairment. To evaluate the efficacy, safety and tolerability of galantamine in long-term in Mild Cognitive Disorder. …
Literature
1.
go back to reference Blesa R: Galantamine: therapeutics effects beyond cognition. Dement Geriatr Cogn Disord. 2000, 11 (suppl 1): 28-34. 10.1159/000051229.CrossRefPubMed Blesa R: Galantamine: therapeutics effects beyond cognition. Dement Geriatr Cogn Disord. 2000, 11 (suppl 1): 28-34. 10.1159/000051229.CrossRefPubMed
2.
go back to reference Sramek JJ, Veroff AE, et al: The status of ongoing trials for mild cognitive impairment. Expert Opin Inveting Drugs. 2001, 10 (4): 741-752. 10.1517/13543784.10.4.741.CrossRef Sramek JJ, Veroff AE, et al: The status of ongoing trials for mild cognitive impairment. Expert Opin Inveting Drugs. 2001, 10 (4): 741-752. 10.1517/13543784.10.4.741.CrossRef
Metadata
Title
Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
Authors
Julio Zarra
Luisa Schmidt
Publication date
01-04-2010
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue Special Issue 1/2010
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-9-S1-S99

Other articles of this Special Issue 1/2010

Annals of General Psychiatry 1/2010 Go to the issue